---
schema_version: "secwatch.filing_event.v1"
accession: "0001367644-26-000088"
form_type: "8-K"
ticker: "EBS"
cik: "0001367644"
company_name: "Emergent BioSolutions Inc."
filed_at: "2026-09-01T20:13:12+00:00"
generated_at: "2026-09-01T20:14:05.688095+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Emergent BioSolutions gets $24M BARDA contract modification for CYFENDUS anthrax vaccine

## Summary
- Contract modification valued at ~$24M from BARDA to supply CYFENDUS (Anthrax Vaccine Adsorbed, Adjuvanted) for anthrax preparedness.
- Modification No. 21 to BARDA AV7909 Contract, effective Aug 18, 2026; announced Sept 1, 2026.
- Earlier in 2026, Emergent announced up to $21.5M delivery order for BioThrax to U.S. Department of War.
- CYFENDUS approved by FDA in July 2023 as two-dose anthrax vaccine for post-exposure prophylaxis in adults 18-65.

## SEC filing metadata
- accession: 0001367644-26-000088
- form_type: 8-K
- ticker: EBS
- cik: 0001367644
- company_name: Emergent BioSolutions Inc.
- filed_at: 2026-09-01T20:13:12+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1367644/000136764426000088/0001367644-26-000088-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1367644/000136764426000088/ebs-20260818.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001367644-26-000088
- JSON: https://secwatch.observer/filing/0001367644-26-000088.json
- Plain text: https://secwatch.observer/filing/0001367644-26-000088.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.